For a study, researchers sought to determine the clinical features and treatment results of women with recurrent uterine leiomyosarcoma (uLMS).

They performed retrospective cohort research to assess the clinical traits, treatment results, and prognostic variables of women with recurrent uLMS.

In all, 71 individuals with uLMS that had its initial recurrence were included in the research. Stage I patients made up 55 patients, or 77.5%, stage II in 8 patients, or 11.3% patients, stage III in 3 patients, or 4.2% patients, and stage IV in 5 patients (7.0%), according to the FIGO 2008 distribution by stage at the time of initial presentation. 16.3 months was the median amount of time between the original diagnosis and the first recurrence (range: 1.0-161.9 months). After initial diagnosis, 33.8% (24/71) of patients developed recurrence within a year. The abdominal/pelvic peritoneum was the most frequently diagnosed location of initial recurrence, identified in 47 (66.2%) individuals. In the overall sample, 52 patients (73.2%) underwent secondary cytoreductive surgery (SCS), while 19 patients (26.8%) got systemic treatment. In the SCS subgroup (n=52), 47 patients (90.4%) had a full resection with no remaining disease. 20/52 patients (38.5%) underwent non-genital organ operations. Ten patients (19.2%) underwent thoracic surgery due to lung-only recurrence. Surgery on the bowel or bladder was done in 15.4% and 5.8% of patients, respectively. One patient (1.9%) had liver surgery. About 34.6% of the patients had a blood loss estimate of more than 500 ml. The average number of follow-up months was 38.7. (range: 2.7-317.6 months). The whole cohort’s 5-year OS was 52.9%. Patients who had their first recurrence after receiving their original diagnosis during the first 12 months had a lower 5-year OS than those who had it beyond that time (17.0% vs. 69.1%, P<0.001). Around 5-year OS was 62.0% for the SCS subgroup and 28.0% for the non-SCS subgroup, respectively (P< 0.001). Time to the first recurrence within 12 months was identified by multivariate analysis as an independent predictor of lower 5-year OS in the SCS subgroup (HR=4.60, 95% CI: 1.49-14.4, P = 0.008).

According to the present study, SCS is a significant therapy option for these individuals and appeared to have helped the patients. In the SCS subgroup, the time to the first recurrence within a year is a reliable predictor of a lower 5-year OS.

 

Reference: annalsofoncology.org/article/S0923-7534(22)02592-3/fulltext